AI Article Synopsis
Article Abstract
Background: Direct oral anticoagulants (DOACs) are preferred over warfarin for the treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy and safety of fixed dose regimen of DOACs remains unclear in morbidly obese patient population and are currently not recommended for use in patients with a body mass index (BMI) > 40 kg/m or a weight of >120 kg.
Objective: The goal of this study is to evaluate the use of DOACs in morbidly obese veteran population as compared to warfarin.
Methods: This retrospective single center cohort study included morbidly obese patients weighing >120 kg or BMI > 40 kg/m who were prescribed DOACs or warfarin for AF or VTE between January 1st, 2015 to May 31st, 2018. Data was extracted from the computerized patient record system (CPRS) and the Salem Veterans Affairs Medical Center (SVAMC) data warehouse. The primary outcome was combined incidence of stroke/transient ischemic attack (TIA) and VTE. Secondary outcomes included all-cause mortality, ISTH major bleed and clinically relevant non major bleed as well as primary outcome and ISTH major bleeding analyses in the subgroups of AF and VTE patients.
Results: The study included 190 patients in warfarin group and 214 in DOACs group. Baseline characteristics were mostly well matched except for the follow up duration which was significantly longer in the warfarin group as compared to DOAC (p > 0.001). The annual incidence rate of primary outcome was similar between warfarin and DOACs (3.91% vs.1.61%; RR:2.436; 95% CI 0.85-8.54; p = 0.1543).
Conclusion: This hypothesis generating study suggests that DOAC use may be feasible in morbidly obese patients. Additional studies are necessary to confirm this finding and further guide clinical practice in this area.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.thromres.2020.04.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Glucagon-Like Peptide-1 Receptor Agonists Decrease Medical and Surgical Complications in Morbidly Obese Patients Undergoing Primary TKA.
J Bone Joint Surg Am
December 2024
Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, NY.
Background: Weight optimization methods in morbidly obese patients with a body mass index (BMI) of ≥40 kg/m2 undergoing total knee arthroplasty (TKA) have shown mixed results. The purpose of this study was to evaluate the effect of perioperative use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with a BMI of ≥40 kg/m2 undergoing primary TKA.
Methods: Using an administrative claims database, patients with morbid obesity undergoing primary TKA were stratified into GLP-1 RA use for 3 months before and after the surgical procedure (treatment group) and GLP-1 RA non-use (control group), and were matched on the basis of patient age, gender, diagnosis of type-2 diabetes mellitus, and Charlson Comorbidity Index (CCI).
Mid-term radiographic evaluation of a monoblock trabecular metal tibia following total knee arthroplasty in obese and morbidly obese patients.
Arch Orthop Trauma Surg
December 2024
Henry Community Health, 2200 Forest Ridge Parkway, New Castle, IN47362, USA.
Background: Indications for primary total knee arthroplasty (TKA) have become more inclusive of morbidly obese patients, however, higher rates of complications and lower implant survival have also been reported in this population. The purpose of this study was to investigate the mid-term survival, clinical, and radiographic outcomes of a cementless trabecular metal monoblock tibial component in severely obese patients.
Methods: This was a retrospective study of class II and III obese (BMI > 35) patients who received a cementless primary TKA.
HIGH BODY MASS INDEX IS ASSOCIATED WITH LOWER ADALIMUMAB SERUM LEVELS AND HIGHER DISEASE ACTIVITY IN NON-INFECTIOUS UVEITIS.
Am J Ophthalmol
December 2024
Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Purpose: Adalimumab, a TNF-alpha inhibitor, is the only FDA-approved biologic for non-infectious uveitis (NIU). However, treatment responses vary, potentially due to interindividual pharmacokinetic differences influenced by body mass index (BMI). This study aimed to evaluate the impact of BMI on adalimumab serum trough levels and therapeutic efficacy in patients with NIU.
View Article and Find Full Text PDFEffect of Enhanced Recovery After Surgery in Morbidly Obese Patients Undergoing Free Flap Breast Reconstruction.
J Reconstr Microsurg
December 2024
Plastic Surgery, University of Virginia Health System, Charlottesville, United States.
Background: Enhanced Recovery After Surgery (ERAS) pathways have been widely implemented across many surgical practices, including autologous breast reconstruction. However, the benefits of ERAS in the morbidly obese population have yet to be defined.
Methods: A retrospective chart review of patients undergoing deep inferior epigastric artery perforator (DIEP) flap breast reconstruction at our institution from 2017 to 2022 was performed.
Objective: To compare patient outcomes across body mass index (BMI) subgroups in the setting of recent tracheotomy.
Methods: This retrospective chart review included patients over 18 years old who underwent tracheotomy placement between February 2017 and March 2020. Patients were divided into five groups based on BMI: underweight, normal weight, overweight, obese, and morbidly obese.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!